The antitumour activity of ZD9331, a non-polyglutamatable quinazoline thymidylate synthase inhibitor.
Jackman
A L
AL
CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey, UK.
Kimbell
R
R
Brown
M
M
Brunton
L
L
Harrap
K R
KR
Wardleworth
J M
JM
Boyle
F T
FT
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity*; D001692:Biological Transport; D017322:Clinical Trials, Phase II as Topic; D004351:Drug Resistance; D006801:Humans; D007939:Leukemia L1210 / Q000188:drug therapy; D008727:Methotrexate / Q000378:metabolism / Q000627:therapeutic use / Q000633:toxicity; D051379:Mice; D011799:Quinazolines / Q000378:metabolism / Q000627:therapeutic use* / Q000633:toxicity*; D013329:Structure-Activity Relationship; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors*
D000970:Antineoplastic Agents; D011799:Quinazolines; C094299:ZD 9331; D013940:Thymidylate Synthase; D008727:Methotrexate